03.14.2022
Emergent Announces Additions to Leadership Team
Emergent is pleased to announce the addition of two senior leaders to its CDMO and Quality & Compliance organizations.
03.11.2022
The Path to Reemergence
Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently shared his insights with Pharma...
07.23.2021
Arrival of the Groninger INTEGRA
With the expansion of our viral drug product manufacturing facility in Rockville, Maryland well underway, we have begun...
05.12.2021
Rockville, MD Expansion Progress
Our drug product manufacturing facility in Rockville, Maryland is undergoing an expansion that will soon house a...
02.13.2021
Emergent Enters Into a New CDMO Agreement with Providence Therapeutics to Provide Fill/Finish Drug Product Manufacturing
Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing...
01.25.2021
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. ...
10.01.2020
Bloomberg: The Way Ahead
Emergent BioSolutions, a Wells Fargo Corporate & Investment Banking customer since 2011, helps governments respond to health...
09.01.2020
All Hands on Deck for Fill/Finish of Vaccines and Therapeutics
“Emergent has a long, successful history of working with the US government to develop, manufacture, and deliver safe and...
07.07.2020
EMERGENT IN THE NEWS: COVID-19 General Coverage
Read the latest news coverage of Emergent's insights and involvement in the fight against COVID-19. Last Updated: Thursday,...
06.02.2020
Emergent Continues to Expand Role in Support of Development and Manufacturing of COVID-19 Vaccines
Emergent BioSolutions recently announced that it has been issued a task order under an existing contract with the Biomedical...
04.14.2022
Molecule to Market: Inside the Outsourcing Space
Emergent recently had the pleasure of participating in the Molecule to Market Podcast hosted by Ramen Sehgal from from ra...
07.05.2021
Lyophilized products are on the rise: Here's what you need to know
There has been a steady increase in demand for lyophilized products in recent years. Due in large part to biologic drug...
05.27.2021
Supporting the Production of Next-Gen Therapies
“The Vanrx SA25 Aseptic Filling Workcell is a state-of-the-art machine, providing our clients with a high level of sterility...
03.12.2021
Genetic Vaccine Platforms Demonstrate Their Potential
In a recent Pharmaceutical Technology article, Emergent experts provide their insights on selection of technologies for vaccine...
12.01.2020
BioPharm Intl Regulatory Sourcebook: GMPs Guide COVID-19 Vaccine Manufacturing
Excerpt taken from BioPharm International October 2020 Regulatory Sourcebook article titled: GMPs Guide COVID-19 Vaccine...
11.30.2020
Factoring Stability in the Biologic Drug Mix
Jee Look, senior director of drug product development for Emergent BioSolutions recently contributed to an article in ...
10.31.2020
Gene therapy solution: The value of a CDMO as your end-to-end partner
With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past...
09.21.2020
Strategizing for Rapid Changeovers in Biologics Manufacturing
Syed T. Husain, senior vice president and CDMO business unit head at Emergent BioSolutions recently contributed to an editorial...
07.29.2020
COVID-19: 'Pandemic-ready' set-up placing Emergent apart in CDMO Space
In a recent article with BioProcess International, Syed T. Husain, senior vice president & CDMO business unit head at Emergent...
09.14.2021
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
- Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...
07.06.2020
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
- Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large...
06.18.2020
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
- Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing...
06.01.2020
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
- Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...
04.01.2020
Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
- CDMO agreement for NanoFlu to support pathway to licensure
- Expanded collaboration now includes NanoFlu and COVID-19 vaccine...
03.19.2020
Vaxart AGREEMENT for Experimental Oral Vaccine Candidate for Coronavirus Disease
GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered...
03.19.2020
Novavax agreement for Experimental Vaccine Candidate for Coronavirus Disease
GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered...